SAN DIEGO, May 20, 2016 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that
he is retiring from the Board of Directors effective just prior to
the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a
member of the Board of Directors for over thirteen years serving in
various capacities on the audit, compensation, and nominating and
corporate governance committees.
"Tom has been an integral member of the Board and played an
instrumental role in helping build Neurocrine to the company it is
today," said Kevin C. Gorman,
President and Chief Executive Officer. "We wish him well in
retirement, and want to thank him for his years of dedication and
advice."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and valbenazine, a vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial rights
to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with Neurocrine's business and finances in general, as well as
risks and uncertainties associated with NBI-98854 (valbenazine)
development. Specifically, the risks and uncertainties the Company
faces include risks that valbenazine development activities may not
be completed on time or at all; risks that valbenazine development
activities may be delayed for regulatory or other reasons, may fail
to demonstrate that valbenazine is safe and effective, or may not
be predictive of real-world results or of results in subsequent
clinical trials; risks that valbenazine regulatory submissions may
not occur or be submitted in a timely manner; risks that
valbenazine may not obtain regulatory approval or that the U.S.
Food and Drug Administration or regulatory authorities outside the
U.S. may make adverse decisions regarding valbenazine; risks that
valbenazine may be precluded from commercialization by the
proprietary rights of third parties, or have unintended side
effects, adverse reactions or incidents of misuse; risks associated
with the Company's dependence on third parties for development and
manufacturing activities related to valbenazine; risks that the
Company will be unable to raise additional funding, if required, to
complete development of valbenazine; risks and uncertainties
relating to competitive products and technological changes that may
limit demand for valbenazine; and other risks described in the
Company's quarterly report on Form 10-Q for the quarter ended
March 31, 2016. Neurocrine disclaims
any obligation to update the statements contained in this press
release after the date hereof.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-retirement-of-w-thomas-mitchell-from-the-board-of-directors-300272054.html
SOURCE Neurocrine Biosciences, Inc.